Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CAM menopause treatments

This article was originally published in The Tan Sheet

Executive Summary

Individual studies of various complementary and alternative medicine treatments for menopause symptoms suggested some benefit, but the overall data of 70 randomized controlled trials of CAM menopause therapies are "insufficient to support the effectiveness" of any of these treatments, according to an evidence review published in the Journal of the American Medical Association July 24. The 48 studies of biologically based treatments such as soy phytoestrogens and black cohosh produced mixed results, but the smaller numbers of studies examining "mind-body, energy, manipulative, and body-based therapies and whole medical systems showed little benefit in treating menopausal symptoms," Anne Nedrow, MD, Oregon Health & Science University, Portland, Ore., et al., state. The authors recommend that CAM menopause therapies be tested for safety and efficacy, as demand for treatments increase with an aging society...

You may also be interested in...



UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer

With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.

Topics

UsernamePublicRestriction

Register

PS099599

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel